

AF



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/628,804	07/28/2003	Arlene R. Howe	38-21(15060)C	4557
27161	7590	10/07/2005	EXAMINER	
MONSANTO COMPANY 800 N. LINDBERGH BLVD. ATTENTION: G.P. WUELLNER, IP PARALEGAL, (E2NA) ST. LOUIS, MO 63167			KUBELIK, ANNE R	
			ART UNIT	PAPER NUMBER
			1638	

DATE MAILED: 10/07/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/628,804

Applicant(s)

HOWE ET AL.

Examiner

Anne R. Kubelik

Art Unit

1638

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on 25 July 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-39 is/are pending in the application.
- 4a) Of the above claim(s) 34-37 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-33, 38 and 39 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☒ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- ☐ Notice of Informal Patent Application (PTO-152)
- ☐ Other: _____

DETAILED ACTION

1. Applicant's election with traverse of Group I (claims 1-33 and 38-39) in the reply filed on 25 July 2005 is acknowledged. The traversal is on the ground(s) that it would not be an undue burden to search all claims. This is not found persuasive because, as the vessels recited in the kit Group II are not used in the method of Group I, and as the method of Group I uses selective agents not found in the kit of Group II, the searches are not coextensive; a search on one would not find all art on the other. Thus, searching both would be an undue burden.

The requirement is still deemed proper and is therefore made FINAL.

Claims 34-37 are withdrawn from consideration as being drawn to a nonelected invention

Claim Objections

2. Claims 2-16, 18-33 and 38-39 are objected to because

There should be a comma before "wherein" in claims 2-16, 18-33 and 38-39, line 1.

In claims 7 and 24 --geneticin-- is misspelled as "genenticin"

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 1-2, 4-19, 21-33 and 38-39 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of detecting the presence of an NPTII selectable marker gene in a plant using kanamycin and paromomycin and certain

Art Unit: 1638

organosilicone concentrations, does not reasonably provide enablement for a method of detecting the presence of any selectable marker gene in a plant using all the listed selective agents and organosilicone concentrations. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims, as stated in the last Office action.

The claims are drawn very broadly to a method of detecting the presence of any selectable marker gene product in any plant by applying or contacting a plant of any species and of any age with any amount of any selective agent and any organosilicone surfactant and assessing the resulting appearance of the plant. Some of the claims specify a particular surfactant, surfactant concentration, selective agent, selectable marker gene, or plant type or species, but no claims are limited to all these features, so that, for example, the claims that specify a particular surfactant at a particular concentration, call for the use of the method in any plant with any selectable marker gene/selectable agent combination. The specification lacks guidance for carrying out the method of detecting a selectable marker gene, particularly one other than the NPTII gene.

The direct application of a selectable marker and a surfactant to plants is unpredictable. The instant specification indicates that use of the organosilicone SILWET L-77 at concentrations above 0.1% resulted in obvious yellowing of the leaves of nontransgenic corn seedlings of an unspecified age (page 13, lines 5-6). All the further examples use SILWET L-77 concentrations in the range of 0.01%-0.06%, so the effect of the yellowing caused by the higher SILWET L-77 concentrations on the ability to score treated plants for necrosis and/or bleaching caused by the presence of a selective agent was not determined. Severe yellowing would likely interfere with

the ability to score the plants, and the specification gives no guidance on how to score treated plants when high SILWET L-77 concentrations are used.

The behavior of different organosilicone surfactants is unpredictable. The bulk of the examples are done using a single organosilicone surfactant, SILWET L-77, but example 9 (pg 18-19 of the specification) shows the results when kanamycin/paromomycin mixture was applied to nontransformed corn seedlings using different SILWET surfactants. In the tests with one of the surfactants, SILWET L-7002, one plant out of six tested showed no visible bleaching. This suggests that not all organosilicone surfactants would behave as SILWET L77 does, and that false positives would be seen when some organosilicone surfactants are used.

These claims encompass all or many herbicide and antibiotic selectable agents and corresponding resistance genes. However, not all antibiotics to which even a single resistance gene confers resistance would respond in the same manner. The instant specification indicates that while the NPTII gene product confers resistance to a number of antibiotics including genenticin and kanamycin, genenticin did not give a clearly defined bleaching and/or necrosis response on nontransgenic corn seedlings, while kanamycin, at least at some concentrations, did (pg 13 of the specification, example 2). Additionally, paromomycin, when used with SILWET L-77 as the only antibiotic on nontransformed corn plants produced a number of plants with no symptoms, i.e, it generated false positives (table on pg 16 of the specification). If three antibiotics that correspond to a single resistance gene behave unpredictably, it is reasonable to expect that antibiotics or herbicides that correspond to other resistance genes would also behave in an unpredictable manner, and that guidance for their use would be required.

The amount of antibiotic and organosilicone needed as a function of the age of the plants is unpredictable. Example 4 of the specification (pg 15) indicates that corn seedlings of different ages needed very different amounts of antibiotic to produce visible necrosis or bleaching. For 1-week-old corn seedlings, 0.01 mg of antibiotic produced “very dramatic bleaching and necrosis” (lines 11-12), while for corn seedlings two weeks older, 2 to 2.5 times that amount of antibiotic produced only “some bleaching and necrosis” on the leaves (lines 18-20). Plants, corn or otherwise, older than that were not tested, and as the amount of bleaching and necrosis decreased with age of the plant, even when increased amounts of antibiotic were used, guidance would be needed for the application of the method to corn plants older than 3 weeks, soybeans other than 17 days old, and to other plants of any age.

Some markers that work in selection of transformed dicots do not work in selection of monocots. Dekeyser et al (1989, Plant Physiol. 90:217-223) teach that selection of untransformed rice calli by certain selective agents, including kanamycin, is very concentration dependent (pg 221-222, including figure 6). Hauptmann et al (1988, Plant Physiol. 86:602-606) teach that selection of NPTII transformants of *Lolium multiflorum* only works with G418 (geneticin) (pg 602, 1st full paragraph), which as discussed above, did not work in this assay, and that the Pennisetum spp. tested had high natural resistance to kanamycin (pg 603, right column). Zhou et al (1995, Plant Cell Rep. 15: 159-163) summarize some of the problems with the use of various selective agents in the transformation of monocots, and state that “few selectable markers are currently available for genetic transformation of monocot species” (paragraph spanning the columns on pg 159). Thus, guidance is required for the use of this method for the detection of any selectable marker gene product in any plant.

Art Unit: 1638

Given the claim breath, unpredictability, and lack of guidance as discussed above, undue experimentation would have been required by one skilled in the art to develop and evaluate this method for detecting the presence of any selectable marker gene product in any plant. There is no claim enabled for all the features noted above.

5. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

6. Claims 11-15 and 28-32 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 11-15 and 28-32 contain the trademark/trade name SILWET. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112, second paragraph. See *Ex parte Simpson*, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade names are used to identify/describe specific organosilicones and, accordingly, the identification/description is indefinite.

Double Patenting

Art Unit: 1638

7. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.

8. Claims 3 and 20 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1 and 13 of prior U.S. Patent No. 6,600,088. This is a double patenting rejection.

9. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

10. Claims 1-2, 4-19, 21-33 and 38-39 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 2-12 and 14-27 of U.S. Patent No. 6,600,088. An obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but an examined application claim not is patentably distinct from the reference claim(s) because the examined claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d

Art Unit: 1638

1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985).

Although the conflicting claims are not identical, they are not patentably distinct from each other. The method of detecting the presence of the selectable marker gene product NPTII protein, as claimed in the issued patent, is a species of the genus of methods of detecting the presence of the selectable marker gene product as claimed in the issued patent.

Conclusion

11. No claim is allowed.

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik, whose telephone number is (571) 272-0801. The examiner can normally be reached Monday through Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached at (571) 272-0745.

The central fax number for official correspondence is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.


For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Application/Control Number: 10/628,804

Page 9

Art Unit: 1638

Anne R. Kubelik, Ph.D.
September 22, 2005

A handwritten signature in black ink, appearing to read 'Anne R. Kubelik', written in a cursive style.

**ANNE KUBELIK, PH.D.
PRIMARY EXAMINER**